Enovis Corp Dossier - Source-backed chat

Enovis Corp

ENOVNYSE

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.29

Intrinsic Value $49.52median of 3 methodsbased on filings through 3 Jul 2026

Market Price $18.05Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 174% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+174%)

Data confidence Sign in to view data confidence

Market Cap $1B

Enterprise Value $2.3B

Shares Outstanding 57.6M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Enovis Corporation (NYSE: ENOV) has successfully transitioned from an industrial conglomerate into a pure-play medical technology growth company. The company is uniquely positioned across the musculoskeletal care continuum, operating through two segments: Prevention & Recovery (P&R) and Reconstructive (Recon). While GAAP earnings have been heavily impacted by non-cash goodwill impairment charges in 2024 and 2025, the underlying business demonstrates robust organic growth, particularly in high-margin reconstructive extremities and international markets. The integration of LimaCorporate S.p.A. and the commercial rollout of the ARVIS augmented-reality surgical navigation system serve as key catalysts for margin expansion and market share gains in the rapidly growing Ambulatory Surgery Center (ASC) channel.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$28.00

Mean target$40.83

High · most bullish analyst$55.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects persistent macroeconomic headwinds, including severe tariff impacts, raw material inflation (titanium and specialty polymers), and supply chain disruptions. Slower elective procedure volumes or tighter hospital capital budgets could delay high-ticket robotic and navigation system purchases, limiting ARVIS adoption. In this scenario, organic revenue growth slows to low-single digits, integration synergies are delayed, and margins are compressed, keeping the stock range-bound near its recent lows.

Base CaseCentral scenario

The base case assumes Enovis successfully executes its 2026 financial outlook, delivering organic revenue growth of 4% to 6% to reach total revenue of approximately $2.31 billion to $2.37 billion. Adjusted EBITDA is expected to land between $425 million and $435 million, supported by a 50 basis point margin expansion as the company absorbs tariff and freight headwinds. Free cash flow conversion is projected to remain at or above 25%, allowing the company to continue deleveraging its balance sheet toward its target of approximately 3x net debt to adjusted EBITDA.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong organic growth momentum in the Reconstructive segment, particularly in U.S. extremities and international reconstruction.
Differentiated product portfolio spanning the entire continuum of orthopedic care, from prevention to post-surgical rehabilitation.
Strategic expansion into high-growth channels like Ambulatory Surgery Centers (ASCs) with capital-efficient technology like ARVIS.
Clear path to margin expansion and deleveraging through the integration of LimaCorporate and operational efficiency programs.

Key Investment Risks

High leverage and debt service requirements following major acquisitions like LimaCorporate.
Exposure to macroeconomic pressures, including tariff increases, freight inflation, and raw material cost volatility.
Intense competition from significantly larger, well-capitalized medical device incumbents in the reconstructive joint market.
Risk of further non-cash goodwill impairment charges if the stock price or market capitalization experiences sustained declines.

Thesis Invalidation Triggers

Organic revenue growth falling below 3% for consecutive quarters.
Failure to achieve the targeted 25% free cash flow conversion in fiscal 2026.
A significant delay or failure in capturing the projected cost and commercial synergies from the LimaCorporate integration.
Loss of market share in key reconstructive product lines to major competitors.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.